Actinogen Medical (ASX:ACW) Presentation, FNN Investor Event, September 2018, Sydney

Company Presentations

Actinogen Medical Limited (ASX:ACW) Managing Director and CEO, Dr Bill Ketelbey presents an update on the company's lead Alzheimer Phase II drug candidate XanADu and its expanded clinical development program for Xanamem.

Key points:

  • Xanamem lead compound for the treatment of Alzheimer's disease
  • Also considered for other cortisol-associated cognitive impairment
  • Reducing brain cortisol production
  • Experienced board and management
  • Expert clinical and scientific advisory boards
  • Phase II trial currently underway
  • Substantial institutional investment
  • A huge market with significant unmet need

For more, watch the Managing Director and CEO, Dr Bill Ketelbey present.